Periodic Reporting for period 2 - PlugBioIn (Plug and play enzymes for an accelerated uptake of Biocatalysis in the Pharmaceutical Industry)
Reporting period: 2016-01-01 to 2017-06-30
The results were disseminated on scientific and more business oriented conferences in oral lectures and on booths with purpose-made flyers. The product was also featured in two webinars, which attracted a broad community. A webpage was created at the product section of c-LEcta’s homepage to provide information, a contact address and finally an online ordering tool for the product. The direct communication with customers was highly valuable to adjust our offers and services. Other technology services of c-LEcta, like enzyme production or a custom enzyme development, could be addressed as well with these communications. The “Plug & Play Biocats” thus serves as an attractant for our further services as well and helps to strengthen our business.
Scientific papers featuring the “Plug & Play Biocats” were realized with academic and industrial colleagues. Those publications from independent researches present the uniqueness and advantages of our enzymes and gain important impact in the community. A notable work was published by scientist from Pfizer (which is among the world's largest pharmaceutical companies) who did a comparative study with enzyme collections from various providers and rated our ATA and ADH enzymes as the most useful for their application.
The main exploitation system is the provision of the enzymes collection in small scale format which is used by the customers in screenings. This entry point should be as simple as possible. Accordingly, the prices for the enzymes in small scale were reduced in order to make costs no hurdle for the companies to implement our enzymes in their screen. Our aim is that the enzymes end up as a hit and negotiations of large scale provision of our product can start. Unfortunately, this has happened less frequent than we had expected. This is partially due to slow implementation of new products by the pharmaceutical companies. Since we entered several agreements meanwhile and the quality of the product developed in this project is getting very positive feedback from the community, we expect that a constant increase in sales in the coming years will take place.
In summary, we developed a high quality set of enzymes which are now routinely used by the main pharmaceutical companies. This is a great success of the development we could realize within the PlugBioIn project and will help us to realize sustainable business in the near future.
The development in this project is thus strengthening the biotechnological and pharmaceutical industry in providing superior processes and economical savings. Moreover, it delivers environmentally more friendly processes with direct impact on the ecosystem and human health.